Additional Data Reported for Ongoing Phase I/II AUTO3 Clinical Trials Treating DLBCL

The data was presented at the EHA-EBMT 2nd European CAR T-Cell Meeting, which took place on January 30, 2020 in Barcelona, Spain, and showed encouraging signs of a manageable safety profile in adults with relapsed/refractory DLBCL.

Source: CancerNetwork - February 4, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news